Insider Transactions in Q1 2023 at Arrowhead Pharmaceuticals, Inc. (ARWR)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2023
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
11,350
-59.06%
|
$363,200
$32.65 P/Share
|
|
Feb 27
2023
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
875
-6.31%
|
$28,000
$32.62 P/Share
|
|
Jan 10
2023
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+13.4%
|
-
|
|
Jan 10
2023
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+20.1%
|
-
|
|
Jan 10
2023
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+7.31%
|
-
|
|
Jan 10
2023
|
Victoria Vakiener Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+25.25%
|
-
|
|
Jan 10
2023
|
Victoria Vakiener Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,764
-10.27%
|
-
|
|
Jan 10
2023
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+17.61%
|
-
|
|
Jan 10
2023
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+5.96%
|
-
|
|
Jan 10
2023
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,867
+29.05%
|
-
|
|
Jan 09
2023
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
3,200
-9.95%
|
$96,000
$30.0 P/Share
|
|
Jan 05
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
13,803
-3.42%
|
$510,711
$37.4 P/Share
|
|
Jan 05
2023
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
15,000
-1.77%
|
$555,000
$37.39 P/Share
|
|
Jan 04
2023
|
Tracie Oliver Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
500
+0.7%
|
-
|
|
Jan 04
2023
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+13.17%
|
-
|
|
Jan 04
2023
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+13.14%
|
-
|
|
Jan 04
2023
|
Martin Javier San Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+28.37%
|
-
|
|
Jan 04
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+22.62%
|
-
|
|
Jan 03
2023
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
17,500
-0.58%
|
$682,500
$39.11 P/Share
|
|
Jan 03
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
10,338
-0.85%
|
$403,182
$39.05 P/Share
|